An information technology executive and strategist, Stephen Guistwite currently serves as chief operating officer of StratITsphere, a data center and cloud computing company based in Katy, Texas. Steve Guistwite’s charitable interests include the Juvenile Diabetes Research Foundation, an organization that seeks to cure Type 1 diabetes.
Research sponsored by the Juvenile Diabetes Research Foundation includes the development of artificial pancreas systems. Artificial pancreas development seeks to replicate the pancreas’ ability to balance blood-glucose levels and insulin levels. Such technology would vastly increase the quality of life of patients with diabetes by reducing the taxing need to actively manage blood sugar levels by tightly controlling food intake, exercise, and stress exposure.
The Artificial Pancreas Project began in 2006. Breaking into a largely unexplored area and incorporating advanced technologies, JDRF has succeeded in bringing an artificial pancreas system through preliminary FDA review, with outpatient trials currently in progress.
In the next five years, JDRF will need as much as $85 million to complete the artificial pancreas project. The organization possesses 503(c)(3) status, and donors may receive tax benefits for their contributions.
Research sponsored by the Juvenile Diabetes Research Foundation includes the development of artificial pancreas systems. Artificial pancreas development seeks to replicate the pancreas’ ability to balance blood-glucose levels and insulin levels. Such technology would vastly increase the quality of life of patients with diabetes by reducing the taxing need to actively manage blood sugar levels by tightly controlling food intake, exercise, and stress exposure.
The Artificial Pancreas Project began in 2006. Breaking into a largely unexplored area and incorporating advanced technologies, JDRF has succeeded in bringing an artificial pancreas system through preliminary FDA review, with outpatient trials currently in progress.
In the next five years, JDRF will need as much as $85 million to complete the artificial pancreas project. The organization possesses 503(c)(3) status, and donors may receive tax benefits for their contributions.